PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma
Status:
Not yet recruiting
Trial end date:
2025-05-31
Target enrollment:
Participant gender:
Summary
The purpose of this Phase III, Multicenter, Randomized Controlled Clinical Trial is to
evaluate the efficacy and safety of PD-1 inhibitor Plus GP chemotherapy as Neoadjuvant
Therapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma.
Phase:
Phase 3
Details
Lead Sponsor:
Guangxi Medical University
Collaborators:
Affiliated Hospital of North Sichuan Medical College First People's Hospital of Yulin Fourth Affiliated Hospital of Guangxi Medical University Guigang People's Hospital Hainan People's Hospital Second affiliated hospital of Guangxi Medical University Wuzhou Red Cross Hospital Yulin Red Cross Hospital